DREAM Program Expands Community, Career Development for Health Equity Researchers from Underrepresented Minorities uky.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uky.edu Daily Mail and Mail on Sunday newspapers.
LEXINGTON, Ky. (March 15, 2021) The Center for Health Equity Transformation (CHET) at the University of Kentucky is now accepting applications for its health equity-focused pilot grants through April 1. The awards are open to health equity studies affecting vulnerable groups or populations affected by health disparities.
Applications are only accepted from CHET core faculty and affiliates. To learn more about how to become a CHET affiliate, visit https://chet.med.uky.edu/chet-pilot-grants.
Depending on applications, CHET hopes to fund up to two proposals this year, with one pilot study in conjunction with the new UNITE Research Priority Area. One of the missions of UNITE is to support research focused on racial disparities, racial health equity and social and racial justice that will result in impactful scholarly outputs and extramural funding for sustainability.
Disparities Researchers Equalizing Access for Minorities) Scholars Program, which supports the career development of exceptional under-represented minority pre-docs, post-docs, and assistant professors who are committed to health equity research.
Applications are due Feb. 12, 2021. Five DREAM Scholars will be selected from a competitive application process. Predoctoral trainees, postdoctoral trainees and assistant professors in good standing are eligible to apply. Priority will be given to applicants who are racial/ethnic and sexual/gender minorities in research. The DREAM Scholar program supports the preparation of the next generation of health equity researchers to address the health outcomes of the diverse population of Kentucky and beyond,” said Lovoria Williams, Ph.D., director of the DREAM Scholars Program and associate professor and endowed research professor in cancer health equity in the UK College of Nursing.
The Pfizer/BioNTech COVID-19 vaccine is breaking some healthcare barriers, but not all.
In less than one year, the vaccine has passed through three required phases of a clinical trial and is currently ready to be mass-produced across the world. Great Britain became the first Western Nation to vaccinate its citizens this week. As soon as this weekend, hospitals across the United States will be able to start vaccinating frontline workers, pending approval by the U.S. Food and Drug Administration (FDA).
Advertisement:
However, there s one peculiar caveat to the Pfizer/BioNTech vaccine and to other major vaccine trials, too: none included pregnant women in their clinical trials. Indeed, not one of the vaccines expected to be approved by the FDA in the next couple weeks, including the Pfizer/BioNTech one, have been tested on pregnant women directly, leaving a cohort of people who are vulnerable to COVID-19 with no direct information on how the vaccine will affect them or their fet